Table 3.
Salvage RT patient group characteristics
| Characteristics | Salvage RT group |
|---|---|
| Patients (n) | 17 |
| Age (median) | 69 (58–84) |
| Radical prostatectomy | 17 |
| TNM stage | |
| pT1-T2 | 11 |
| pT3a-b | 5 |
| pT4 | 1 |
| pN1 | 1 |
| pNx | 9 |
| Mx | 17 |
| Gleason score | |
| 6–7 | 8 |
| 8–9 | 8 |
| Positive surgical margins after radical prostatectomy | 5 |
| Pre-PSMA-PET/CT PSA (ng/ml) (median) | 2.8 (0.1–21.8) |
| Postoperative PSA (ng/ml) (median) | 0.7 (0–7) |
| PSA (ng/ml) at PSMA-PET/CT in PET positive pts | 1.6 (0.4–13.8) |
| PSA (ng/ml) at PSMA-PET/CT in PET negative pts | 0.6 (0.1–1) |
| PSMA-PET/CT revealed metastases in | |
| FR only | 6 |
| Lymph nodes | 7 |
| Bones | 1 |
| FR and lymph nodes | 1 |
Pts, patients; PSA, prostate-specific antigen; PSMA-PET/CT, prostate-specific membrane antigen positron emission tomography/computed tomography; ADT, androgen deprivation therapy; LN, lymph nodes; FR, fossa recurrence; RT, radiation therapy